Stem cell showdown: donor or self? new trial aims to improve lymphoma outcomes

NCT ID NCT07253129

Recruiting now Disease control Sponsor: Shanghai General Hospital, Shanghai Jiao Tong University School of Medicine Source: ClinicalTrials.gov ↗

First seen Jun 27, 2026 · Last updated Jun 27, 2026

Summary

This study compares two types of stem cell transplants for people with peripheral T-cell lymphoma whose cancer only partially responded to first treatment. One group receives their own stem cells, the other receives cells from a matched donor. The goal is to see which approach leads to better two-year survival without cancer progression. The trial plans to enroll 88 participants across multiple centers.

What this could mean

Our plain-language read of the trial. This is informational only — not medical advice or a prediction.

Active substance: stem cell transplant (either from a donor or the patient's own cells)
What this could lead to: If successful, this could show which type of stem cell transplant offers better long-term control for patients whose lymphoma only partially shrank after initial treatment.
What could go wrong: This is a relatively small, early-stage study (88 people) and results may not apply to all patients. Stem cell transplants carry serious risks like infection, graft-versus-host disease, and organ damage.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for ANAPLASTIC LARGE CELL LYMPHOMA, ALK-NEGATIVE are added.

Our safety recommendation!

By submitting, you agree to our Terms of use

Conditions

The condition(s) this trial relates to.

ALK-negative anaplastic large cell lymphoma mature T-cell and NK-cell non-Hodgkin lymphoma Nodal T-follicular helper cell lymphoma, follicular type peripheral T-cell lymphoma, not otherwise specified

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

PERIPHERAL T-CELL LYMPHOMA

Contacts and locations

Locations

Shanghai General Hospital
RECRUITING

Shanghai, Shanghai Municipality, 200080, China

More trials for these conditions

Other studies related to the condition(s) this trial covers.